Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes
Authors:
- T. IdaTIT. Ida
- T. AsaiTAT. Asai
- N. MaedaNMN. Maeda
- N. OkuNON. Oku
- 1 August 2008
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 360 (1-2) , 219-224
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Liposomal encapsulated anti-cancer drugsAnti-Cancer Drugs, 2005
- Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxiaCancer Letters, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Drug Delivery Systems: Entering the MainstreamScience, 2004
- SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Causes Accumulation of Phosphorylated ERK Kinases and Inhibits Their Activity in Vivo and in VitroJournal of Biological Chemistry, 2004
- Tumorigenesis and the angiogenic switchNature Reviews Cancer, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in RatsPharmaceutical Research, 2000
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Anti-AngiogenesisAnnals of Surgery, 1972